EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY 4.0

Pharmacokinetics and Bioequivalence of a Novel Extended‐Release Formulation of Methylphenidate Hydrochloride for Attention‐Deficit/Hyperactivity Disorder

Ann C Childress, Ahmad Al-Sabbagh, Jeffrey H Newcorn

Clinical Pharmacology in Drug Development · 2025

DOI: 10.1002/cpdd.1577 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Ann C Childress und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Psychiatry and Behavioral Medicine, Las Vegas, NV, USA. Hauptthemen laut MEDLINE: Methylphenidate, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extended‐release (ER) formulations of the stimulant methylphenidate are commonly used to treat attention‐deficit/hyperactivity disorder in both children and adults. Previous studies have shown that the clinical effectiveness of long‐acting methylphenidate formulations is closely tied to the drug's pharmacokinetic (PK) profile, highlighting the need for consistency in drug exposure. ODX‐methylphenidate ER uses an osmotic pump design to provide controlled release of drug over the course of the day. In these similarly designed 4‐period replicate crossover studies, the PK profile of ODX‐methylphenidate ER was compared to the reference product, osmotic release oral system (OROS)‐methylphenidate ER, in healthy subjects in the fasted state. In the first trial (N = 60), a single 72‐mg tablet of ODX‐methylphenidate ER was compared to two 36‐mg tablets of OROS‐methylphenidate ER, while in the second trial (N = 36), a single 54‐mg tablet of ODX‐methylphenidate ER was compared to a 54‐mg tablet of OROS‐methylphenidate ER. The 2 studies had very comparable results, demonstrating similar PK parameters for the 2 products, including during the critical 7‐12‐hour postdose window. Statistical bioequivalence between the 2 formulations was confirmed for maximum drug concentration, area under the concentration‐time curve from time 0 to 3 hours after dosing (AUC 0‐3 h ), AUC from 3 to 7 hours after dosing, AUC from 7 to 12 hours after dosing, and AUC from time 0 extrapolated to infinity in both trials. Safety and tolerability were similar for both products and in both trials, with no serious adverse events reported.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethylphenidateCentral Nervous System StimulantsAttention Deficit Disorder with HyperactivityHumansDelayed-Action PreparationsTherapeutic EquivalencyCross-Over StudiesMaleAdultFemaleYoung AdultArea Under CurveMiddle AgedAdolescentAdministration, OralTabletsHealthy Volunteers

Stichwörter der Autor:innen

ADHDattention‐deficit/hyperactivity disorderextended‐releasemethylphenidatepharmacokinetics

Substanzen

MethylphenidateDelayed-Action PreparationsCentral Nervous System StimulantsTablets

Autor:innen und Institutionen

  • Center for Psychiatry and Behavioral Medicine, Las Vegas, NV, USA.
  • Alora Pharmaceuticals, LLC, Alpharetta, GA, USA.
  • Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Zitieren

APA

Childress, A. C., Al-Sabbagh, A., & Newcorn, J. H. (2025). Pharmacokinetics and Bioequivalence of a Novel Extended‐Release Formulation of Methylphenidate Hydrochloride for Attention‐Deficit/Hyperactivity Disorder. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1577

Vancouver

Childress AC, Al-Sabbagh A, Newcorn JH. Pharmacokinetics and Bioequivalence of a Novel Extended‐Release Formulation of Methylphenidate Hydrochloride for Attention‐Deficit/Hyperactivity Disorder. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1577

BibTeX
@article{Childress2025,
  author = {Childress, Ann C and Al-Sabbagh, Ahmad and Newcorn, Jeffrey H},
  title = {Pharmacokinetics and Bioequivalence of a Novel Extended‐Release Formulation of Methylphenidate Hydrochloride for Attention‐Deficit/Hyperactivity Disorder},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2025},
  doi = {10.1002/cpdd.1577}
}
Kostenlos starten →